SEC Form 4 · accession 0001179110-17-007134
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter S Ringrose
Director
Period of report
May 12, 2017
Accepted (ET)
May 12, 2017 · 6:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001034842
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.61 | May 12, 2017 | A | 40,000 | A | — | May 12, 2027 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The shares vest monthly over twelve (12) months from the date of grant.